Cellular Senescence and Vascular Calcification: Mechanistic Crosstalk and Potential of Dual-Targeting Strategies
- 1Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China
- 2Institute of Cardiovascular Diseases, Jiangsu University, Zhenjiang 212001, China
- 3Department of Pathology, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China
Abstract
Vascular calcification (VC), a key predictor of cardiovascular morbidity and mortality, is an active cell-mediated pathological process deeply coupled with cellular senescence. This review systematically dissects the mechanisms by which senescent vascular smooth muscle cells, endothelial cells and macrophages drive VC progression via phenotypic switching, intercellular crosstalk, and endothelial–mesenchymal transition and clarifies the extensive signaling crosstalk and heterogeneous regulation between cellular senescence and VC. Nevertheless, these two biological processes do not inevitably occur in parallel, and experimental evidence indicates that they may diverge in some settings. We further summarize representative senotherapeutic agents that concurrently suppress cellular senescence and VC, including fisetin, dasatinib plus quercetin, metformin, sodium-glucose cotransporter 2 inhibitors, and liraglutide, and elaborate their core regulatory targets such as AMP-activated protein kinase, silent information regulator 1/6, nuclear factor kappa B and nuclear factor erythroid 2-related factor 2. Of note, direct experimental evidence demonstrating whether these pharmacological interventions attenuate VC via modulating SASP remains limited. Finally, we address key challenges in this field and provide novel perspectives for senescence-associated VC therapeutic strategies.
Related
- Crosstalk between gut microbiota-associated metabolites and adaptive immunity in cholecystitis: a conceptual mechanistic framework and potential therapeutic implications
- Natural Products and Their Derivatives in Cancer, Cardiovascular disease, and COVID-19: Mechanistic Insights, Formulation Strategies, and Therapeutic Potential
- The Current Landscape of Exosome-Based Strategies for Breast Cancer Brain Metastasis: From Mechanistic Insights to Therapeutic Potential.
- Vitamin K2 and Cardiovascular Calcification: Mechanistic Foundations, Conflicting Clinical Evidence, and Unresolved Questions
- Effects and Therapeutic Strategies of Intra-Hepatic Cellular Senescence and Regeneration
BibTeX
@article{xu2026cellular,
title = {{Cellular Senescence and Vascular Calcification: Mechanistic Crosstalk and Potential of Dual-Targeting Strategies}},
author = {Jia Xu and Ling Chen and Yi Liu and Mayibai Mushajiang and Limin Xie and Zhongqun Wang},
journal = {Biomolecules},
year = {2026},
month = nov,
doi = {10.3390/biom16111631},
url = {https://www.mdpi.com/2218-273X/16/11/1631},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cellular Senescence and Vascular Calcification: Mechanistic Crosstalk and Potential of Dual-Targeting Strategies
AU - Jia Xu
AU - Ling Chen
AU - Yi Liu
AU - Mayibai Mushajiang
AU - Limin Xie
AU - Zhongqun Wang
PY - 2026
DA - 2026/11/09
JO - Biomolecules
DO - 10.3390/biom16111631
UR - https://www.mdpi.com/2218-273X/16/11/1631
AB - Vascular calcification (VC), a key predictor of cardiovascular morbidity and mortality, is an active cell-mediated pathological process deeply coupled with cellular senescence. This review systematically dissects the mechanisms by which senescent vascular smooth muscle cells, endothelial cells and macrophages drive VC progression via phenotypic switching, intercellular crosstalk, and endothelial–mesenchymal transition and clarifies the extensive signaling crosstalk and heterogeneous regulation between cellular senescence and VC. Nevertheless, these two biological processes do not inevitably occur in parallel, and experimental evidence indicates that they may diverge in some settings. We further summarize representative senotherapeutic agents that concurrently suppress cellular senescence and VC, including fisetin, dasatinib plus quercetin, metformin, sodium-glucose cotransporter 2 inhibitors, and liraglutide, and elaborate their core regulatory targets such as AMP-activated protein kinase, silent information regulator 1/6, nuclear factor kappa B and nuclear factor erythroid 2-related factor 2. Of note, direct experimental evidence demonstrating whether these pharmacological interventions attenuate VC via modulating SASP remains limited. Finally, we address key challenges in this field and provide novel perspectives for senescence-associated VC therapeutic strategies.
SN - 2218-273X
ER -